The impact of tyrosine kinase inhibitors on chronic myeloid leukemia stem cells and the implication on discontinuation

BCR-ABL1 tyrosine kinase inhibitors (TKIs) are selective therapies for patients with chronic myeloid leukemia (CML) and induce deep molecular response (DMR). However, approximately 60% of patients ...